SCHEDULE: BlackRock Boosts PTC Therapeutics Stake to 14.8%

BlackRock, Inc. has filed an Amendment No. 12 to Schedule 13G, reporting a 14.8% beneficial ownership in PTC Therapeutics, Inc.'s common stock.

Summary

• BlackRock, Inc. reported beneficial ownership of 11,904,696 shares of PTC Therapeutics, Inc. common stock.
• This represents 14.8% of the total outstanding common stock of PTC Therapeutics, Inc.
• BlackRock holds sole voting power over 11,767,632 shares and sole dispositive power over 11,904,696 shares.
• The filing is an Amendment No. 12 to Schedule 13G, indicating a continued significant stake.
• iShares Core S&P Small-Cap ETF, a BlackRock entity, holds more than 5% of the total outstanding common stock.
• The event requiring this filing occurred on November 30, 2025, with the filing submitted on December 4, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects, beyond the implicit confidence of a large institutional investor maintaining a significant stake.

Positives

• BlackRock, a prominent global asset manager, maintains a substantial 14.8% beneficial ownership in PTC Therapeutics, Inc., which can be interpreted as a continued vote of confidence in the company's long-term prospects.
• The significant institutional ownership by BlackRock, through various subsidiaries including iShares Core S&P Small-Cap ETF, provides a degree of market stability and investor reassurance.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding PTC Therapeutics, Inc.'s future performance.

Industry Context

BlackRock's continued significant stake in PTC Therapeutics, Inc. reflects its ongoing investment strategy within the biotechnology sector, where large institutional holdings are common for established or promising companies. As a major asset manager, BlackRock's positions are closely watched by the market.

Stakeholder Impact

• Shareholders: BlackRock's continued substantial ownership may provide reassurance and signal long-term confidence in PTC Therapeutics, Inc., potentially influencing other investors' perceptions.
• Market: The disclosure of a significant institutional stake can contribute to market stability and liquidity for PTC Therapeutics, Inc.'s common stock.

Key Dates

Keywords

BlackRock, PTC Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Asset Management, Biotechnology